Benzinga | Feb 26, 2021 10:40AM EST

Guggenheim Initiates Coverage On Akero Therapeutics with Buy Rating, Announces Price Target of $54

Guggenheim analyst Etzer Darout initiates coverage on Akero Therapeutics (NASDAQ:AKRO) with a Buy rating and announces Price Target of $54.